FDA
-
-
-
-
-
-
-
Vera Therapeutics (VERA) PT Raised to $125 at H.C. Wainwright
-
-
-
-
-
-
-
TD Cowen on Vera Therapeutics (VERA): 'Launch prep remains on track; we have confidence in a clean approval'
-
-
-
-
-
-
-
Vera Therapeutics receives FDA priority review for IgA nephropathy drug
-
-
-
-
-
-
-
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy
-
-
-
-
-
-
-
Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
-
-
-
-
-
-
-
Vera Therapeutics (VERA) Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN
-
-
-
-
-
-
-
Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study
-
332,015 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

